Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer

Core Insights - Allarity Therapeutics has initiated a Phase 2 clinical trial for stenoparib, with the second patient dosed shortly after the trial's launch, indicating strong engagement from investigators [1][2] - Stenoparib is being evaluated for its potential benefits in patients with advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer, a group with limited treatment options [2][4] - The trial aims to further assess the unique WNT-modulating mechanism of action of stenoparib and advance Allarity's proprietary Drug Response Predictor (DRP) companion diagnostic [3][4] Company Overview - Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, a dual-targeted inhibitor for advanced ovarian cancer [6] - The company utilizes its DRP technology to identify patients who are likely to benefit from stenoparib based on their cancer's gene expression signature [5][6] - Allarity has exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. [4]